NCT06725381招募中1 期
A Phase 1 Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of SKB571 for Injection in Subjects With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 138
- 试验地点
- 15
- 主要终点
- Number of subjects achieving Dose-limiting toxicity (DLT)
研究概览
简要总结
This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor .
详细描述
This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects aged 18-75 years at the time of signing the informed consent form
- •Subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumors .
- •Subjects with at least one measurable lesion assessed by the investigator according to RECIST v1.
- •Subjects with Eastern Cooperative Oncology Group (ECOG) status score of 0 or
- •Subjects who are assessed by the investigator to have an expected survival of ≥ 3 months.
- •Subjects who have adequate organ function.
- •Subjects who have recovered from all toxicities due to prior therapy .
- •Male and female subjects must agree to use highly effective contraception methods during the study treatment.
- •Subjects who voluntarily sign the informed consent form.
排除标准
- •Subjects with known active or untreated central nervous system (CNS) metastases.
- •Subjects with other malignant tumors within 3 years prior to the first dose.
- •Subjects with history of major cardiovascular, cerebrovascular, or thromboembolic disease.
- •Subjects with known active pulmonary tuberculosis.
- •Subjects with human immunodeficiency virus (HIV) infection, or any known active viral hepatitis, or hepatitis B or hepatitis C.
- •Subjects with major surgery within 28 days prior to the first dose.
- •Subjects with known allergy or hypersensitivity to SKB571 or its excipients.
- •Subjects with clinically severe lung injuries due to pulmonary complications.
- •Subjects with a history of allogeneic tissue/solid organ transplant.
- •Uncontrolled pleural effusion, pericardial effusion, or ascites effusion requiring repeated drainage.
- •Subjects who have received live vaccines within 30 days prior to the first dose of study treatment, or who are scheduled to receive live vaccines during the study.
- •Subjects who have received strong cytochrome P450 (CYP3A4) inhibitors or inducers, or BCRP inhibitors within 2 weeks prior to the first dose of study treatment or within 5 half-lives of known drug, whichever is longer.
- •Subjects who have received chemotherapy, immunotherapy, or biological therapy within 4 weeks prior to the first dose of study treatment.
- •Subjects with active infection requiring systemic anti-infective therapy within 14 days prior to the first dose of study treatment.
- •Subjects with any disease requiring systemic treatment with corticosteroids (prednisone at doses > 10 mg/d or similar drugs with equivalent doses) or other immunosuppressive therapy within 14 days prior to the first dose of study treatment.
- •Subjects have received an investigational agent or has used an investigational device within 28 days prior to initial dose administration of SKB
- •Subjects whose condition deteriorates rapidly before the first dose, such as a severe physical impariment or a change in ECOG score no longer meeting the inclusion criteria.
- •Subjects with a known history of psychosis or drug abuse that will preclude the subject from completing the study.
- •Any condition that, in the opinion of the investigator, will interfere with the assessment of study treatment or the safety of the subject or the interpretation of the study results.
研究组 & 干预措施
Dose escalation
Experimental
干预措施: SKB571 (Drug)
结局指标
主要结局
Number of subjects achieving Dose-limiting toxicity (DLT)
时间窗: From data of initial dose until up to 21 days for treatment
DLT is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 and is at least possibly related to study drug.
次要结局
- Objective Response Rate (ORR)(Up to 24 months)
- Progression Free Survival (PFS)(Up to 24 months)
- Duration of Response (DOR)(Up to 24 months)
- Overall Survival (OS)(Up to 24 months)
研究者
研究点 (15)
Loading locations...
相似试验
招募中
1 期
A Study of SKB518 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT06428331Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.150
招募中
1 期
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell CarcinomaRenal Cell CarcinomaNCT06182735Fudan University9
招募中
1 期
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant TumorsLocally Advanced, Recurrent or Metastatic MalignanciesNCT06390774Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.180
已完成
1 期
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal MalignanciesPeritoneal MalignanciesNCT03443674Clover Biopharmaceuticals AUS Pty Ltd7
已完成
1 期
A Study to Evaluate the Safety of K-755 in Healthy VolunteersHealthyNCT03414294Kowa Company, Ltd.121